Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.

Benzer Materyaller

• Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.
  Yazar:: Jackson, G. H., ve diğerleri
  Baskı/Yayın Bilgisi: (1994)
• Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
  Yazar:: Seymour, L. K., ve diğerleri
  Baskı/Yayın Bilgisi: (1994)
• High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
  Yazar:: Zulian, G. B., ve diğerleri
  Baskı/Yayın Bilgisi: (1989)
• Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database
  Yazar:: Desai, Ami V., ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• The Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/ Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: “A Single-Center Experience”
  Yazar:: Ali Eser, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-05-01)